Wealth Enhancement Advisory Services LLC Has $3.96 Million Stock Holdings in Cellebrite DI Ltd. $CLBT

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 1,749.9% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 256,196 shares of the company’s stock after buying an additional 242,347 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Cellebrite DI were worth $3,958,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of CLBT. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Cellebrite DI in the first quarter worth approximately $60,939,000. Invesco Ltd. increased its stake in shares of Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Cellebrite DI by 749.9% during the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company’s stock worth $29,508,000 after acquiring an additional 1,340,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Cellebrite DI during the first quarter valued at $22,428,000. Finally, Royal Bank of Canada grew its stake in Cellebrite DI by 11,705.0% in the first quarter. Royal Bank of Canada now owns 824,226 shares of the company’s stock valued at $16,015,000 after purchasing an additional 817,244 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Down 0.9%

Shares of Cellebrite DI stock opened at $18.30 on Friday. The company’s fifty day simple moving average is $15.73 and its 200-day simple moving average is $16.95. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The company has a market cap of $4.38 billion, a price-to-earnings ratio of -24.08, a PEG ratio of 3.35 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same period last year, the business earned $0.10 earnings per share. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on CLBT. Needham & Company LLC dropped their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 15th. JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, September 13th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Cellebrite DI presently has a consensus rating of “Buy” and a consensus price target of $21.75.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.